Vinva Investment Management Ltd Buys New Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Vinva Investment Management Ltd purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 10,057 shares of the medical equipment provider's stock, valued at approximately $1,060,000.

A number of other large investors have also recently bought and sold shares of the stock. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $25,000. Dunhill Financial LLC boosted its position in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 218 shares in the last quarter. Brooklyn Investment Group bought a new stake in Zimmer Biomet during the third quarter worth about $35,000. Kentucky Trust Co bought a new stake in Zimmer Biomet during the fourth quarter worth about $39,000. Finally, OFI Invest Asset Management acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth approximately $40,000. 88.89% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.95% of the company's stock.

Remove Ads

Zimmer Biomet Stock Down 0.7 %

NYSE ZBH traded down $0.74 during trading hours on Tuesday, reaching $110.50. 1,296,857 shares of the company's stock were exchanged, compared to its average volume of 1,496,400. The company has a market capitalization of $22.00 billion, a price-to-earnings ratio of 24.83, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The company's 50-day moving average is $106.86 and its two-hundred day moving average is $106.86. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $133.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business posted $2.20 EPS. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet's payout ratio is currently 21.57%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. JMP Securities restated a "market outperform" rating and set a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Royal Bank of Canada cut their price target on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Stifel Nicolaus increased their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Finally, Raymond James dropped their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.